{"entity":{"id":"nct06099782","kind":"trial","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) is a phase 2 interventional study registered as NCT06099782 by Merck Sharp & Dohme LLC, with 147 participants enrolled, started 2023-12-26 and due to reach its primary completion in 2025-04-09. Interventions recorded: Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06099782","url":"https://clinicaltrials.gov/study/NCT06099782"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","rcc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06099782","phase":"2","setting":"A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)","sponsor":"Merck Sharp & Dohme LLC","enrolled":147,"outcomes":[]},"route":"/trials/nct06099782/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}